Adrienne M Flanagan

List of Publications by Year
in descending order

164	25,290	19608 61	6979 154
papers	citations	h-index	g-index

174	174	174	31617
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Osteoclast-rich lesions of bone. , 2022, , 631-647.		0
2	Overlapping morphological, immunohistochemical and genetic features of superficial CD34-positive fibroblastic tumor and PRDM10-rearranged soft tissue tumor. Modern Pathology, 2022, 35, 767-776.	2.9	14
3	Osteosarcoma: Novel prognostic biomarkers using circulating and cell-free tumour DNA. European Journal of Cancer, 2022, 168, 1-11.	1.3	8
4	Signatures of copy number alterations in human cancer. Nature, 2022, 606, 984-991.	13.7	154
5	EWSR1-SMAD3 fibroblastic tumour of bone: expanding the clinical spectrum. Skeletal Radiology, 2021, 50, 445-450.	1.2	4
6	<scp>MYC</scp> amplifications are common events in childhood osteosarcoma. Journal of Pathology: Clinical Research, 2021, 7, 425-431.	1.3	12
7	<scp>DNA</scp> methylationâ€based profiling of bone and soft tissue tumours: a validation study of the â€˜<scp>DKFZ</scp> Sarcoma Classifierâ€™. Journal of Pathology: Clinical Research, 2021, 7, 350-360.	1.3	25
8	An overview and update on soft tissue lesions of the head and neck. Diagnostic Histopathology, 2021, 27, 171-181.	0.2	1
9	An overview and update on bone lesion in craniofacial bones. Diagnostic Histopathology, 2021, 27, 216-225.	0.2	1
10	Notochordal Tumors. Surgical Pathology Clinics, 2021, 14, 619-643.	0.7	6
11	A pan-cancer landscape of somatic mutations in non-unique regions of the human genome. Nature Biotechnology, 2021, 39, 1589-1596.	9.4	6
12	<scp>AZD8055</scp> enhances in vivo efficacy of afatinib in chordomas. Journal of Pathology, 2021, 255, 72-83.	2.1	9
13	Circulating tumour DNA is a promising biomarker for risk stratification of central chondrosarcoma with IDH1/2 and GNAS mutations. Molecular Oncology, 2021, 15, 3679-3690.	2.1	4
14	Sarcoma classification by DNA methylation profiling. Nature Communications, 2021, 12, 498.	5.8	237
15	Benign Bone-Forming Tumors. Surgical Pathology Clinics, 2021, 14, 549-565.	0.7	4
16	Alternative tissue fixation for combined histopathological and molecular analysis in a clinically representative setting. Histochemistry and Cell Biology, 2021, 156, 595-607.	0.8	1
17	Frequent alterations in p16/CDKN2A identified by immunohistochemistry and FISH in chordoma. Journal of Pathology: Clinical Research, 2020, 6, 113-123.	1.3	39
18	Extraâ€axial skeletal poorly differentiated chordoma: a case report. Histopathology, 2020, 76, 924-927.	1.6	7

#	Article	IF	Citations
19	<scp>H3K27me3</scp> expression and methylation status in histological variants of malignant peripheral nerve sheath tumours. Journal of Pathology, 2020, 252, 151-164.	2.1	20
20	Drivers underpinning the malignant transformation of giant cell tumour of bone. Journal of Pathology, 2020, 252, 433-440.	2.1	21
21	Inhibition of Histone H3K27 Demethylases Inactivates Brachyury (TBXT) and Promotes Chordoma Cell Death. Cancer Research, 2020, 80, 4540-4551.	0.4	33
22	Sarcoma and the 100,000 Genomes Project: our experience and changes to practice. Journal of Pathology: Clinical Research, 2020, 6, 297-307.	1.3	20
23	Frequency of Pathogenic Germline Variants in Cancer-Susceptibility Genes in Patients With Osteosarcoma. JAMA Oncology, 2020, 6, 724.	3.4	139
24	A novel next generation sequencing approach to improve sarcoma diagnosis. Modern Pathology, 2020, 33, 1350-1359.	2.9	20
25	Genomics of MPNST (GeM) Consortium: Rationale and Study Design for Multi-Omic Characterization of NF1-Associated and Sporadic MPNSTs. Genes, 2020, 11, 387.	1.0	16
26	HuR/ELAVL1 drives malignant peripheral nerve sheath tumor growth and metastasis. Journal of Clinical Investigation, 2020, 130, 3848-3864.	3.9	38
27	Radiological Features of Giant Cell Tumours of Bone. Cureus, 2020, 12, e8793.	0.2	2
28	Comorbidities and Pregnancy Do Not Affect Local Recurrence in Patients With Giant Cell Tumour of Bone. Cureus, 2020, 12, e9164.	0.2	1
29	Undifferentiated pleomorphic sarcomas with PRDM10 fusions have a distinct gene expression profile. Journal of Pathology, 2019, 249, 425-434.	2.1	23
30	Systematic Review of Clinical, Radiologic, and Histologic Features of Benign Notochordal Cell Tumors: Implications for Patient Management. World Neurosurgery, 2019, 130, 13-23.	0.7	7
31	Synovial chondromatosis and soft tissue chondroma: extraosseous cartilaginous tumor defined by FN1 gene rearrangement. Modern Pathology, 2019, 32, 1762-1771.	2.9	67
32	Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort. European Journal of Cancer, 2019, 109, 36-50.	1.3	354
33	Activating mutations in the MAPâ€kinase pathway define nonâ€ossifying fibroma of bone. Journal of Pathology, 2019, 248, 116-122.	2.1	49
34	Undifferentiated Sarcomas Develop through Distinct Evolutionary Pathways. Cancer Cell, 2019, 35, 441-456.e8.	7.7	82
35	Chromosome segregation errors generate a diverse spectrum of simple and complex genomic rearrangements. Nature Genetics, 2019, 51, 705-715.	9.4	145
36	RARE-29. AZD8055 ENHANCES IN VIVO EFFICACY OF AFATINIB IN CHORDOMAS. Neuro-Oncology, 2019, 21, vi227-vi227.	0.6	1

#	Article	IF	Citations
37	FOS Expression in Osteoid Osteoma and Osteoblastoma. American Journal of Surgical Pathology, 2019, 43, 1661-1667.	2.1	50
38	PRDM10-rearranged Soft Tissue Tumor. American Journal of Surgical Pathology, 2019, 43, 504-513.	2.1	35
39	An update of molecular pathology of bone tumors. Lessons learned from investigating samples by next generation sequencing. Genes Chromosomes and Cancer, 2019, 58, 88-99.	1.5	67
40	Clinically actionable mutation profiles in patients with cancer identified by whole-genome sequencing. Journal of Physical Education and Sports Management, 2018, 4, a002279.	0.5	21
41	Genomeâ€wide association study identifies the GLDC/IL33 locus associated with survival of osteosarcoma patients. International Journal of Cancer, 2018, 142, 1594-1601.	2.3	31
42	Rearrangement bursts generate canonical gene fusions in bone and soft tissue tumors. Science, 2018, 361, .	6.0	121
43	Recurrent rearrangements of FOS and FOSB define osteoblastoma. Nature Communications, 2018, 9, 2150.	5.8	106
44	Dedifferentiated Chondrosarcoma Demonstrating Osteosarcomatous Differentiation. Oncology Research and Treatment, 2018, 41, 456-460.	0.8	14
45	Pathology of paediatric bone tumours. Surgery, 2017, 35, 2-9.	0.1	2
46	H3F3A (Histone 3.3) G34W Immunohistochemistry. American Journal of Surgical Pathology, 2017, 41, 1059-1068.	2.1	153
47	Post-translational regulation contributes to the loss of LKB1 expression through SIRT1 deacetylase in osteosarcomas. British Journal of Cancer, 2017, 117, 398-408.	2.9	13
48	Recurrent mutation of IGF signalling genes and distinct patterns of genomic rearrangement in osteosarcoma. Nature Communications, 2017, 8, 15936.	5.8	179
49	A diagnostic approach to bone tumours. Pathology, 2017, 49, 675-687.	0.3	15
50	Molecular testing of sarcomas. Diagnostic Histopathology, 2017, 23, 431-441.	0.2	0
51	The driver landscape of sporadic chordoma. Nature Communications, 2017, 8, 890.	5.8	115
52	Digital PCR analysis of circulating tumor DNA: a biomarker for chondrosarcoma diagnosis, prognostication, and residual disease detection. Cancer Medicine, 2017, 6, 2194-2202.	1.3	26
53	Soft tissue angiofibroma: Clinicopathologic, immunohistochemical and molecular analysis of 14 cases. Genes Chromosomes and Cancer, 2017, 56, 750-757.	1.5	33
54	IDH-mutant glioma specific association of rs55705857 located at 8q24.21 involves MYC deregulation. Scientific Reports, 2016, 6, 27569.	1.6	26

#	Article	IF	Citations
55	EGFR inhibitors identified as a potential treatment for chordoma in a focused compound screen. Journal of Pathology, 2016, 239, 320-334.	2.1	73
56	Mutational signatures of ionizing radiation in second malignancies. Nature Communications, 2016, 7, 12605.	5.8	214
57	The H3F3 K36M mutant antibody is a sensitive and specific marker for the diagnosis of chondroblastoma. Histopathology, 2016, 69, 121-127.	1.6	109
58	Unscrambling the genomic chaos of osteosarcoma reveals extensive transcript fusion, recurrent rearrangements and frequent novel TP53 aberrations. Oncotarget, 2016, 7, 5273-5288.	0.8	60
59	Clinical outcome in patients with peripherallyâ€sited atypical lipomatous tumours and dedifferentiated liposarcoma. Journal of Pathology: Clinical Research, 2015, 1, 106-112.	1.3	9
60	Diagnostic value of H3F3A mutations in giant cell tumour of bone compared to osteoclastâ€rich mimics. Journal of Pathology: Clinical Research, 2015, 1, 113-123.	1.3	135
61	Integrated genomic and transcriptomic analysis of human brain metastases identifies alterations of potential clinical significance. Journal of Pathology, 2015, 237, 363-378.	2.1	98
62	Categorization of cancer through genomic complexity could guide research and management strategies. Journal of Pathology, 2015, 236, 397-402.	2.1	4
63	Mutations in <scp>IDH</scp>1 and <scp>IDH</scp>2 are not present in sporadic ovarian sex cordâ€“stromal tumours. Histopathology, 2015, 66, 897-898.	1.6	0
64	Mutations Preventing Regulated Exon Skipping in MET Cause Osteofibrous Dysplasia. American Journal of Human Genetics, 2015, 97, 837-847.	2.6	22
65	Isocitrate dehydrogenase 1 mutations (IDH1) and p16/CDKN2A copy number change in conventional chondrosarcomas. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2015, 466, 217-222.	1.4	37
66	A Genome-Wide Scan Identifies Variants in NFIB Associated with Metastasis in Patients with Osteosarcoma. Cancer Discovery, 2015, 5, 920-931.	7.7	88
67	Next-generation sequencing is highly sensitive for the detection of beta-catenin mutations in desmoid-type fibromatoses. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2015, 467, 203-210.	1.4	34
68	Osteoclast-rich lesions of bone: a clinical and molecular overview. , 2015, , 257-272.		1
69	A phase II trial to assess the activity of gemcitabine and docetaxel as first line chemotherapy treatment in patients with unresectable leiomyosarcoma. Clinical Sarcoma Research, 2015, 5, 13.	2.3	44
70	Frequent somatic transfer of mitochondrial DNA into the nuclear genome of human cancer cells. Genome Research, 2015, 25, 814-824.	2.4	69
71	GNAS mutations are not detected in parosteal and low-grade central osteosarcomas. Modern Pathology, 2015, 28, 1336-1342.	2.9	47
72	Preclinical Characterization of Novel Chordoma Cell Systems and Their Targeting by Pharmocological Inhibitors of the CDK4/6 Cell-Cycle Pathway. Cancer Research, 2015, 75, 3823-3831.	0.4	73

#	Article	IF	Citations
73	Origins and functional consequences of somatic mitochondrial DNA mutations in human cancer. ELife, 2014, 3, .	2.8	318
74	Assessment of patient-derived tumour xenografts (PDXs) as a discovery tool for cancer epigenomics. Genome Medicine, 2014, 6, 116.	3.6	22
75	Processed pseudogenes acquired somatically during cancer development. Nature Communications, 2014, 5, 3644.	5.8	86
76	Imputation and subset-based association analysis across different cancer types identifies multiple independent risk loci in the TERT-CLPTM1L region on chromosome 5p15.33. Human Molecular Genetics, 2014, 23, 6616-6633.	1.4	90
77	Fibroblastic growth factor receptor 1 amplification in osteosarcoma is associated with poor response to neoâ€adjuvant chemotherapy. Cancer Medicine, 2014, 3, 980-987.	1.3	57
78	Giant Cell Lesions of the Craniofacial Bones. Head and Neck Pathology, 2014, 8, 445-453.	1.3	40
79	Suppression of Deacetylase SIRT1 Mediates Tumor-Suppressive NOTCH Response and Offers a Novel Treatment Option in Metastatic Ewing Sarcoma. Cancer Research, 2014, 74, 6578-6588.	0.4	66
80	Recurrent PTPRB and PLCG1 mutations in angiosarcoma. Nature Genetics, 2014, 46, 376-379.	9.4	269
81	Chiari I malformation associated with Gorham's disease of the skull base. Clinical Neurology and Neurosurgery, 2014, 116, 83-86.	0.6	8
82	Extensive transduction of nonrepetitive DNA mediated by L1 retrotransposition in cancer genomes. Science, 2014, 345, 1251343.	6.0	348
83	Analysis of giant cell tumour of bone cells for Noonan syndrome/Cherubismâ€related mutations. Journal of Oral Pathology and Medicine, 2013, 42, 95-98.	1.4	8
84	Detection of USP6 gene rearrangement in nodular fasciitis: an important diagnostic tool. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2013, 463, 97-98.	1.4	80
85	Frequent mutation of the major cartilage collagen gene COL2A1 in chondrosarcoma. Nature Genetics, 2013, 45, 923-926.	9.4	180
86	Pseudomyogenic (epithelioid sarcoma-like) hemangioendothelioma: characterization of five cases. Skeletal Radiology, 2013, 42, 947-957.	1.2	48
87	Injury Signals Cooperate with Nf1 Loss to Relieve the Tumor-Suppressive Environment of Adult Peripheral Nerve. Cell Reports, 2013, 5, 126-136.	2.9	57
88	Assessment of <scp>MUC</scp>4 expression in primary bone tumours. Histopathology, 2013, 63, 142-143.	1.6	7
89	Genome-wide association study identifies two susceptibility loci for osteosarcoma. Nature Genetics, 2013, 45, 799-803.	9.4	181
90	Screening for Potential Targets for Therapy in Mesenchymal, Clear Cell, and Dedifferentiated Chondrosarcoma Reveals Bcl-2 Family Members and TGFÎ² as Potential Targets. American Journal of Pathology, 2013, 182, 1347-1356.	1.9	53

#	Article	IF	Citations
91	MRI characteristics of lipoma and atypical lipomatous tumor/well-differentiated liposarcoma: retrospective comparison with histology and MDM2 gene amplification. Skeletal Radiology, 2013, 42, 635-647.	1.2	110
92	Meta-analysis of IDH-mutant cancers identifies EBF1 as an interaction partner for TET2. Nature Communications, 2013, 4, 2166.	5.8	152
93	<scp>ERBB</scp>4 confers metastatic capacity in Ewing sarcoma. EMBO Molecular Medicine, 2013, 5, 1087-1102.	3.3	71
94	Ovarian cellular fibroma harbouring an isocitrate dehydrogenase 1 (1<scp>DH</scp>1) mutation in a patient with Ollier disease: evidence for a causal relationship. Histopathology, 2013, 62, 667-670.	1.6	13
95	Distinct H3F3A and H3F3B driver mutations define chondroblastoma and giant cell tumor of bone. Nature Genetics, 2013, 45, 1479-1482.	9.4	667
96	Assessment of integrase interactor 1 (INIâ€1) expression in primary tumours of bone. Histopathology, 2012, 61, 1245-1247.	1.6	7
97	Cobalt from metal-on-metal hip replacements may be the clinically relevant active agent responsible for periprosthetic tissue reactions. Acta Biomaterialia, 2012, 8, 3865-3873.	4.1	50
98	An integrated functional genomics approach identifies the regulatory network directed by brachyury (T) in chordoma. Journal of Pathology, 2012, 228, 274-285.	2.1	83
99	A common single-nucleotide variant in T is strongly associated with chordoma. Nature Genetics, 2012, 44, 1185-1187.	9.4	112
100	High-resolution Whole-Genome Analysis of Skull Base Chordomas Implicates FHIT Loss in Chordoma Pathogenesis. Neoplasia, 2012, 14, 788-IN4.	2.3	37
101	IDH1 mutations are not found in cartilaginous tumours other than central and periosteal chondrosarcomas and enchondromas. Histopathology, 2012, 60, 363-365.	1.6	60
102	Frequency of Mouse Double Minute 2 (MDM2) and Mouse Double Minute 4 (MDM4) amplification in parosteal and conventional osteosarcoma subtypes. Histopathology, 2012, 60, 357-359.	1.6	65
103	Ollier disease and Maffucci syndrome are caused by somatic mosaic mutations of IDH1 and IDH2. Nature Genetics, 2011, 43, 1262-1265.	9.4	368
104	Massive Genomic Rearrangement Acquired in a Single Catastrophic Event during Cancer Development. Cell, 2011, 144, 27-40.	13.5	2,020
105	P63 does not regulate brachyury expression in human chordomas and osteosarcomas. Histopathology, 2011, 59, 1025-1027.	1.6	2
106	Podoplanin expression in adamantinoma of long bones and osteofibrous dysplasia. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2011, 459, 41-46.	1.4	19
107	Role of the transcription factor T (brachyury) in the pathogenesis of sporadic chordoma: a genetic and functionalâ€based study. Journal of Pathology, 2011, 223, 327-335.	2.1	174
108	The role of epidermal growth factor receptor in chordoma pathogenesis: a potential therapeutic target. Journal of Pathology, 2011, 223, 336-346.	2.1	102

#	Article	IF	Citations
109	IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours. Journal of Pathology, 2011, 224, 334-343.	2.1	834
110	Maffucci syndrome: A genomeâ€wide analysis using high resolution single nucleotide polymorphism and expression arrays on four cases. Genes Chromosomes and Cancer, 2011, 50, 673-679.	1.5	6
111	Comparative methylome analysis of benign and malignant peripheral nerve sheath tumors. Genome Research, 2011, 21, 515-524.	2.4	94
112	A Reappraisal of Hemangiopericytoma of Bone; Analysis of Cases Reclassified as Synovial Sarcoma and Solitary Fibrous Tumor of Bone. American Journal of Surgical Pathology, 2010, 34, 777-783.	2.1	55
113	Primary Myxoid Liposarcoma of the Ovary in an Adolescent Girl: A Case Report. International Journal of Gynecological Pathology, 2010, 29, 256-259.	0.9	15
114	Study of the Nonresorptive Phenotype of Osteoclast-like Cells from Patients with Malignant Osteopetrosis: A New Approach to Investigating Pathogenesis. Journal of Bone and Mineral Research, 2010, 15, 352-360.	3.1	35
115	Benefits of molecular pathology in the diagnosis of musculoskeletal disease. Skeletal Radiology, 2010, 39, 213-224.	1.2	17
116	The benefits of molecular pathology in the diagnosis of musculoskeletal disease. Skeletal Radiology, 2010, 39, 105-115.	1.2	10
117	Familial tumoral calcinosis and hyperostosisâ€“hyperphosphataemia syndrome are different manifestations of the same disease: novel missense mutations in GALNT3. Skeletal Radiology, 2010, 39, 63-68.	1.2	32
118	Use of cancerâ€specific genomic rearrangements to quantify disease burden in plasma from patients with solid tumors. Genes Chromosomes and Cancer, 2010, 49, 1062-1069.	1.5	172
119	Hypoxia stimulates osteoclast formation from human peripheral blood. Cell Biochemistry and Function, 2010, 28, 374-380.	1.4	85
120	Liposarcomatous differentiation in malignant peripheral nerve sheath tumor: A case report. Pathology Research and Practice, 2010, 206, 138-142.	1.0	8
121	DOG1 and CD117 are the antibodies of choice in the diagnosis of gastrointestinal stromal tumours. Histopathology, 2010, 57, 259-270.	1.6	162
122	Osteoclast-rich Lesions of Bone. , 2010, , 211-224.		0
123	Nonbacterial osteitis: a clinical, histopathological, and imaging study with a proposal for protocol-based management of patients with this diagnosis. Journal of Orthopaedic Science, 2009, 14, 505-516.	0.5	61
124	GNAS1 mutations occur more commonly than previously thought in intramuscular myxoma. Modern Pathology, 2009, 22, 718-724.	2.9	86
125	Analysis of the fibroblastic growth factor receptor-RAS/RAF/MEK/ERK-ETS2/brachyury signalling pathway in chordomas. Modern Pathology, 2009, 22, 996-1005.	2.9	40
126	Clear cell sarcoma of the mediastinum. Annals of Diagnostic Pathology, 2009, 13, 197-200.	0.6	13

#	Article	IF	Citations
127	Mutations in SH3BP2, the cherubism gene, were not detected in central or peripheral giant cell tumours of the jaw. British Journal of Oral and Maxillofacial Surgery, 2008, 46, 229-230.	0.4	35
128	NF1 loss disrupts Schwann cellâ€“axonal interactions: a novel role for semaphorin 4F. Genes and Development, 2008, 22, 3335-3348.	2.7	52
129	Clear Cell Sarcoma of the Distal Tibialis Posterior Tendon Insertion: A Case Report. Foot and Ankle International, 2008, 29, 445-448.	1.1	4
130	Brachyury Expression in Extra-axial Skeletal and Soft Tissue Chordomas: A Marker that Distinguishes Chordoma From Mixed Tumor/Myoepithelioma/Parachordoma in Soft Tissue. American Journal of Surgical Pathology, 2008, 32, 572-580.	2.1	223
131	Detection of Î²-Catenin Mutations in Paraffin-embedded Sporadic Desmoid-type Fibromatosis by Mutation-specific Restriction Enzyme Digestion (MSRED): an Ancillary Diagnostic Tool. American Journal of Surgical Pathology, 2007, 31, 1299-1309.	2.1	99
132	Detection of SS18-SSX fusion transcripts in formalin-fixed paraffin-embedded neoplasms: analysis of conventional RT-PCR, qRT-PCR and dual color FISH as diagnostic tools for synovial sarcoma. Modern Pathology, 2007, 20, 482-496.	2.9	168
133	Diagnosing an extra-axial chordoma of the proximal tibia with the help of brachyury, a molecule required for notochordal differentiation. Skeletal Radiology, 2007, 36, 59-65.	1.2	51
134	Image-guided percutaneous biopsy of intramedullary lytic bone lesions: utility of aspirated blood clots. European Radiology, 2006, 16, 2120-2125.	2.3	15
135	Subperiosteal hemangioendothelioma of the femur. Skeletal Radiology, 2006, 35, 793-796.	1.2	12
136	Myopericytoma in Kagerâ€™s fat pad. Skeletal Radiology, 2006, 36, 165-169.	1.2	15
137	Limited Rescue of Osteoclast-Poor Osteopetrosis After Successful Engraftment by Cord Blood From an Unrelated Donor. Journal of Bone and Mineral Research, 2005, 20, 2264-2270.	3.1	16
138	A screen of the complete protein kinase gene family identifies diverse patterns of somatic mutations in human breast cancer. Nature Genetics, 2005, 37, 590-592.	9.4	318
139	Synovial chondromatosis of the foot presenting with Lisfranc dislocation. Skeletal Radiology, 2005, 34, 736-739.	1.2	11
140	Atomic force microscopy of collagen structure in bone and dentine revealed by osteoclastic resorption. Ultramicroscopy, 2005, 105, 79-89.	0.8	49
141	Somatic Mutations of the Protein Kinase Gene Family in Human Lung Cancer. Cancer Research, 2005, 65, 7591-7595.	0.4	429
142	Differential Gene Expression in Ovarian Tumors Reveals Dusp 4 and Serpina 5 As Key Regulators for Benign Behavior of Serous Borderline Tumors. Journal of Clinical Oncology, 2005, 23, 7257-7264.	0.8	82
143	Anti-Muˆllerian Hormone Protein Expression Is Reduced during the Initial Stages of Follicle Development in Human Polycystic Ovaries. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 5536-5543.	1.8	144
144	A molecular map of mesenchymal tumors. Genome Biology, 2005, 6, R76.	13.9	119

#	Article	IF	Citations
145	Pathology of Ovarian Cancers in BRCA1 and BRCA2 Carriers. Clinical Cancer Research, 2004, 10, 2473-2481.	3.2	224
146	Kaposi sarcoma herpesvirusâ€“induced cellular reprogramming contributes to the lymphatic endothelial gene expression in Kaposi sarcoma. Nature Genetics, 2004, 36, 687-693.	9.4	414
147	Intragenic ERBB2 kinase mutations in tumours. Nature, 2004, 431, 525-526.	13.7	757
148	In ovarian neoplasms,BRAF, but notKRAS, mutations are restricted to low-grade serous tumours. Journal of Pathology, 2004, 202, 336-340.	2.1	229
149	Chloride Channel ClCN7 Mutations Are Responsible for Severe Recessive, Dominant, and Intermediate Osteopetrosis. Journal of Bone and Mineral Research, 2003, 18, 1740-1747.	3.1	202
150	Upregulation of osteoclast Î±2Î²1 integrin compensates for lack of Î±vÎ²3 vitronectin receptor in Iraqi-Jewish-type Glanzmann thrombasthenia. British Journal of Haematology, 2003, 122, 950-957.	1.2	42
151	Molecular Genetic Evidence for Monoclonal Origin of Bilateral Ovarian Serous Borderline Tumors. American Journal of Pathology, 2003, 162, 1095-1101.	1.9	44
152	Generating Human Osteoclasts In Vitro from Bone Marrow and Peripheral Blood. , 2003, 80, 113-128.		13
153	Mutations of the BRAF gene in human cancer. Nature, 2002, 417, 949-954.	13.7	9,374
154	Is conservative treatment for adenocarcinoma in situ of the cervix safe?. British Journal of Obstetrics and Gynaecology, 2001, 108, 1184-1189.	0.9	39
155	Generation of human osteoclasts in stromal cell-free and stromal cell-rich cultures: differences in osteoclast CD11c/CD18 integrin expression. British Journal of Haematology, 2001, 112, 430-437.	1.2	32
156	Investigation of Ethnic Neutropenia by Assessment of Bone Marrow Colony-Forming Cells. Acta Haematologica, 2001, 105, 32-37.	0.7	26
157	Bronchopulmonary and Mediastinal Leishmaniasis: An Unusual Clinical Presentation of Leishmania donovani Infection. Clinical Infectious Diseases, 2000, 30, 764-769.	2.9	25
158	Allelotype of Uterine Leiomyomas. Cancer Genetics and Cytogenetics, 1999, 114, 89-95.	1.0	33
159	The Gene for Cherubism Maps to Chromosome 4p16.3. American Journal of Human Genetics, 1999, 65, 151-157.	2.6	145
160	Update on the biologic effects of macrophage colony-stimulating factor. Current Opinion in Hematology, 1998, 5, 181-185.	1.2	37
161	Inhibition of bone resorption by bisphosphonates: Interactions between bisphosphonates, osteoclasts, and bone. Calcified Tissue International, 1991, 49, 407-415.	1.5	157
162	Osteoclasts are present in the giant cell variant of malignant fibrous histiocytoma. Journal of Pathology, 1989, 159, 53-57.	2.1	27

#	Article	IF	Citations
163	The multinucleate cells in giant cell granulomas of the jaw are osteoclasts. Cancer, 1988, 62, 1139-1145.	2.0	156
164	Optimizing CRISPR/Cas9 Editing of Repetitive Single Nucleotide Variants. Frontiers in Genome Editing, 0, 4, .	2.7	4